<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1312200327
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Calquence
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Acalabrutinib
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        21385.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AstraZeneca AB" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AstraZeneca AB
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AstraZeneca UK Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What CALQUENCE&reg; is</strong></p><p>CALQUENCE&reg; is a medicine used to treat cancer. CALQUENCE&reg; capsules contain acalabrutinib, an active substance belongs to the Bruton tyrosine kinase (BTK) inhibitor class of anti-cancer medicines.</p><p>&nbsp;</p><p><strong>What CALQUENCE&reg; is used for</strong></p><p>CALQUENCE&reg; is used for the treatment of adults with:</p><ul><li>mantle cell lymphoma (MCL), who have received at least one prior treatment for their cancer.</li><li>Chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL)</li></ul><p><strong>How CALQUENCE&reg; works</strong></p><p>CALQUENCE&reg; blocks BTK and can reduce the number of cancer cells and slow the progression of the disease.<br />CALQUENCE&reg; will only be prescribed to you by a doctor with experience in the use of medicines for cancer.<br />If you have any questions about how CALQUENCE&reg; works or why this medicine has been prescribed for you, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Warnings and precautions</strong><br />Do not take CALQUENCE&reg; if you are Allergic to Acalabrutinib or any of the other ingredients of CALQUENCE&reg;<br />Talk to your doctor before taking CALQUENCE&reg; if you:</p><ul><li>have recently undergone surgery or are about to undergo surgery. Your doctor may stop treatment with CALQUENCE&reg; before a medical, surgical or dental procedure.</li><li>have a bleeding disorder.</li><li>have had liver problems.</li><li>&nbsp;have or had a liver infection (hepatitis B), so that your doctor can look out for signs of reactivation of this infection, such as fever, chills, weakness, confusion, vomiting and jaundice (yellowing of the skin or eyeballs).</li><li>have or had heart rhythm problems.</li><li>are pregnant or planning to become pregnant.</li><li>&nbsp;are breast-feeding or planning to breast-feed.</li></ul><p>If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before taking CALQUENCE&reg;.</p><p><br /><strong>When you take CALQUENCE&reg;, you can have some serious side effects.<br />If you have any of the following, call or see your doctor right away. Your doctor may tell you to decrease your dose, temporarily stop, or completely stop taking CALQUENCE&reg; if you have certain side effects.</strong></p><ul><li>bleeding problems (haemorrhage). Signs and symptoms may include black stools or stools with blood, pink or brown urine, nosebleeds, bruising, unexpected bleeding, vomiting or coughing up blood, dizziness, weakness, confusion, changes in your speech, or headache lasting a long time.</li><li>infections (bacterial, viral, or fungal). Signs and symptoms may include fever or chills, or flu-like symptoms.</li><li>decreased number of blood cell counts. These may be a decreased number of red blood cell counts, decreased number of low white blood cell counts, or decreased number of cells that help blood clot (platelets). Your doctor will check your blood cell counts as needed during treatment with CALQUENCE&reg;.</li><li>second primary cancers. Other cancers may happen during treatment with CALQUENCE&reg;, including cancers of the skin.</li><li>heart rhythm problems (atrial fibrillation or atrial flutter). Signs and symptoms may include fast or abnormal heartbeat, dizziness, feeling faint, chest discomfort, or shortness of breath, or chest discomfort.</li></ul><p><strong>Children and Adolescents</strong><br />The safety and efficacy of CALQUENCE&reg; has not been established in children or adolescents. Do not give this medicine to children or adolescents aged less than 18 years.</p><p><strong>Pregnancy</strong><br />Talk to your doctor before taking CALQUENCE&reg; if you are pregnant, think you may be pregnant or are planning on having a baby. This is because CALQUENCE&reg; may harm your unborn baby. If you are pregnant, you should not take CALQUENCE&reg; .<br />You should not get pregnant while you are taking this medicine.</p><p><strong>Breast-feeding</strong><br />Before taking CALQUENCE&reg; , tell your doctor if you are breast-feeding. It is not known if CALQUENCE&reg; passes into your breast milk. Do not breast-feed during treatment with CALQUENCE&reg; and for 2 days after your final dose of CALQUENCE&reg;.</p><p><strong>Driving and using machines</strong><br />CALQUENCE&reg; is unlikely to affect the ability to drive and use machines. However, if you feel dizzy, weak or tired while taking CALQUENCE&reg;, take special care when driving or using machines</p><p><strong>Taking other medicines</strong><br />Tell your doctor and pharmacist if you are taking or have recently taken any other medicines, including medicines not prescribed, herbal medicines, and supplements.</p><p><strong>CALQUENCE may make you bleed more easily.</strong> This means you should tell your doctor if you take other medicines that increase your risk of bleeding. This includes:</p><ul><li>acetyl salicylic acid and non-steroidal anti-inflammatories (NSAIDs)</li><li>medicines used to prevent blood clots, such as antiplatelet therapy or blood<br />thinners</li></ul><p>Some medicines can affect the levels of CALQUENCE&reg; in your body. Also, CALQUENCE&reg; can affect the way some other medicines work. Tell your doctor if you are taking any of the following:</p><ul><li>Antibiotics used to treat bacterial infections (e.g. clarithromycin)</li><li>Medicines to treat fungal infections (e.g. posaconazole, ketoconazole, itraconazole, voriconazole)</li><li>Medicines used to treat HIV infections (e.g. indinavir)</li><li>Medicines used to treat hepatitis C (e.g. telaprevir)</li><li>Rifampin, an antibiotic used to treat bacterial infections</li><li>Medicines used to prevent seizures or to treat epilepsy (e.g. carbamazepine,<br />phenytoin)</li><li>St. John&rsquo;s wort, a herbal medicine, used for instance to treat depression</li><li>Medicines used to reduce stomach acid, such as antacids (e.g. calcium carbonate), histamine-2 receptor blockers (e.g. ranitidine or famotidine), or certain medicines used to treat severe acid indigestion, such as proton pump inhibitors (e.g. omeprazole)</li><li>Methotrexate, a medicine used to treat immune disorders</li></ul><p>Tell your doctor or pharmacist if you take any of these or any other medicines. The medicines listed here may not be the only ones that could interact with CALQUENCE&reg;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take CALQUENCE&reg; exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><ul><li>The usual dose is one 100 mg capsule twice a day. Doses should be taken about 12 hours apart.</li><li>Swallow the capsule whole with water at approximately the same time each day.</li><li>Take CALQUENCE&reg; with or without food.</li><li>Do not chew, dissolve, or open the capsules.</li><li>Avoid taking medicines called proton pump inhibitors (e.g. omeprazole) while you are taking CALQUENCE&reg;.</li><li>If you take medicine called antacids (e.g. calcium carbonate), take the antacid medicine 2 hours before or 2 hours after you take CALQUENCE&reg;.</li><li>If you take medicines called histamine-2 receptor blockers (e.g. ranitidine or famotidine), take CALQUENCE&reg; 2 hours before the histamine-2 receptor blocker.</li></ul><p><strong>If you take more CALQUENCE&reg; than you should</strong><br />If you may have taken more CALQUENCE&reg; than you should, see a doctor or go to the nearest hospital straight away.</p><p><strong>If you forget to take a dose</strong></p><ul><li>If you miss a dose by less than 3 hours, take the missed dose right away. Take the next dose at your usual time.</li><li>If you miss a dose by more than 3 hours, skip the missed dose. Take the next dose at your usual time.</li><li>Do not take any extra capsules of CALQUENCE&reg; to make up for a missed dose.</li></ul><p><strong>If you stop taking CALQUENCE&reg;</strong></p><p>Do not stop taking CALQUENCE&reg; unless your doctor tells you. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, CALQUENCE&reg; can have side effects, although not everybody gets them. These side effects may occur with certain frequencies, which are defined as follows:</p><p><strong>Very common (affects more than 1 in 10 people) side effects that may occur are:</strong></p><ul><li>infection, signs include fever, chills, or flu-like symptoms</li><li>headache</li><li>diarrhoea</li><li>bruising</li><li>muscle and bone pain</li><li>nausea</li><li>tiredness</li><li>rash</li><li>joint pain</li><li>constipation</li><li>dizziness</li><li>vomiting</li><li>stomach pain</li><li>stomach pain</li><li>new cancers</li></ul><p><strong>The following side effects are very commonly shown in blood tests:</strong></p><ul><li>decreased number of white blood cells</li><li>decreased number of red blood cells</li><li>decreased number of cells that help blood clot (platelets)</li></ul><p><strong>Common (affects up to 1 in 10 people) side effects that may occur are:</strong></p><ul><li>nose bleeds</li><li>non-melanoma skin cancer</li><li>weakness or lack of energy</li><li>fast heart rate, missed heart beats, weak or uneven pulse, dizziness, feeling faint, chest pain, shortness of breath (symptoms of atrial fibrillation)</li></ul><p><strong>Uncommon (affects up to 1 in 100 people) side effects that may occur is:</strong></p><ul><li>condition called tumour lysis syndrome (TLS), when there are unusual levels of chemicals in the blood caused by the fast breakdown of cancer cells have happened during treatment of cancer and sometimes even without treatment.</li></ul><p>Signs of TLS are changes in kidney function, abnormal heartbeat, or seizures</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep this medicine out of the reach and sight of children.</li><li>Store in original package.</li><li>Do not use CALQUENCE&reg; after the expiry date (EXP) which is stated on the white plastic bottle, blister foil, and carton. The expiry date refers to the last day of that month.</li><li>This medicine does not require any special storage conditions.</li><li>Medicines should not be disposed via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substance is acalabrutinib.</li><li>The other ingredients are:<ul><li><u>Capsule Content</u>: microcrystalline cellulose, colloidal silicon dioxide, partially pregelatinized starch (maize), magnesium stearate (E572), and sodium starch glycolate (Type A).</li><li><u>Capsule Shell</u>: gelatine, titanium dioxide (E171), yellow iron oxide (E172), and FD&amp;C Blue 2 (Indigotine/Indigo carmine) (E132).</li><li><u>Printing Ink</u>: Shellac, black iron oxide (E172), propylene glycol (E1520), and ammonium hydroxide.</li></ul></li></ul><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                CALQUENCE® is a hard gelatine capsule with a yellow body and blue cap, marked in black ink with ‘ACA 100 mg’.
CALQUENCE® is supplied in cartons containing blisters 6 x 10 capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>AstraZeneca AB<br />SE-151 85<br />S&ouml;dert&auml;lje<br />Sweden</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>ما هو عقار&nbsp;CALQUENCE&reg;</strong></p><p>CALQUENCE&reg; هو دواء يستخدم لعلاج السرطان . تحتوي كبسولات CALQUENCE&reg; على أكالابروتينيب، وهي مادة فعالة تنتمي إلى فئة مثبط بروتون التيروسين كيناز&nbsp; (BTK)&nbsp;من الأدوية المضادة للسرطان .</p><p><strong>دواعي استعمال&nbsp;CALQUENCE&reg;</strong></p><p>يُستخدم&nbsp;CALQUENCE&reg;&nbsp;لعلاج مرضى الورم اللمفي للخلايا المتدثرة (MCL)&nbsp;لدى البالغين الذين تلقوا علاج سابق&nbsp;واحد على الأقل للسرطان .</p><ul><li>سرطان الدم اللمفاوي المزمن (CLL)&nbsp;لمفومة الخلايا الصغيرة (SLL)</li></ul><p><strong>كيفية عمل&nbsp;&nbsp;CALQUENCE&reg;</strong></p><p>يعمل&nbsp;&nbsp;CALQUENCE&reg;&nbsp;على حصر بروتون التيروسين كيناز ويمكنه أن يقلل من عدد خلايا السرطان ويبطئ من تقدم&nbsp;المرض .&nbsp;</p><p>&nbsp;</p><p>لن يتم وصف&nbsp;CALQUENCE&reg;&nbsp;لك إلا بواسطة طبيب متمرس في استخدام أدوية علاج السرطان .&nbsp;</p><p>إذا كانت لديك أي أسئلة بشأن كيفية عمل&nbsp;CALQUENCE&reg;&nbsp;أو سبب وصف هذا الدواء لك، فاطرحها على طبيبك.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>تحذيرات واحتياطات</strong></p><p>تحدث مع طبيبك قبل تناول&nbsp;CALQUENCE&reg; في حال :</p><ul><li>خضعت مؤخرًا لجراحة أو كنت على وشك الخضوع لجراحة . قد يوقف طبيبك العلاج بعقار&nbsp;CALQUENCE&reg;&nbsp;قبل إجراء طبي أو جراحي أو إجراء متعلق بالأسنان.&nbsp;</li><li>وجود اضطراب نزيف.</li><li>كان لديه مشاكل في الكبد.</li><li>كان لديك عدوى الكبد ( التهاب الكبد B) أو سبق الإصابة بها، حتى يتمكن طبيبك من البحث عن علامات عودة&nbsp;هذه العدوى للنشاط، كالحمى والنافض والضعف والارتباك والتقيؤ واليرقان (اصفرار الجلد أو المقلتين).</li><li>وجود مشكلات في نظم القلب حاليًا أو سابقًا.</li><li>كنتِ سيدة حاملاً أو تنوين الحمل.</li><li>كنتِ ترضعين طفلك طبيعيًا أو تخططين لذلك.</li></ul><p>إذا انطبق عليك أي مما سبق(أو إذا لم تكن متأكدًا)، فتحدّث إلى طبيبك أو الصيدلي أو الممرضة قبل تناول&nbsp;CALQUENCE&reg;.</p><p><strong>عندما تتناول&nbsp;CALQUENCE&reg; ،قد تصاب ببعض الآثار الجانبية الخطيرة.</strong></p><p><strong>إذا كنت تعاني أيٍ مما يلي، فاتصل بطبيبك أو اذهب لزيارته فورًا. قد يطلب إليك طبيبك خفض الجرعة، أو وقف تناول&nbsp;&nbsp;CALQUENCE&reg;&nbsp;مؤقتًا أو نهائيًا، إذا ظهرت عليك آثار جانبية معينة .&nbsp;</strong></p><ul><li>مشكلات النزيف (النزف). قد تشمل العلامات والأعراض براز أسود أو براز مع دم، أو بول وردي أو بني، أو رعاف، أو تكدم، أو نزيف غير متوقع، أو تقيؤ أو سعال دم، أو دوار، أو ضعف، أو ارتباك، أو تغيرات في كلامك، أو صداع يستمر لفترة طويلة.</li><li>عدوى (بكتيرية، أو فيروسية، أو فطرية). قد تشمل العلامات والأعراض حمى أو قشعريرة، أو أعراض شبيهة بالأنفلونزا.</li><li>انخفاض أعداد خلايا الدم. قد تكون هذه الانخفاضات انخفاض في عدد خلايا الدم الحمراء، أو انخفاض في عدد خلايا الدم البيضاء المنخفضة، أو انخفاض في عدد الخلايا التي تساعد الدم على التخثر (الصفيحات). سيفحص&nbsp;طبيبك أعداد خلايا دمك حسب الحاجة خلال العلاج بالعقار&nbsp;CALQUENCE&reg;&nbsp;</li><li>السرطانات الأساسية الثانية. قد تحدث سرطانات أخرى خلال العلاج بالعقار&nbsp;CALQUENCE&reg;،&nbsp; بما في ذلك&nbsp;سرطانات الجلد .</li><li>مشكلات نظم القلب(رجفان أذيني أو رفرفة أذينية). قد تشمل العلامات والأعراض نبض قلب سريع أو غير طبيعي، أو دوار، أو إحساس بالإغماء، أو عدم ارتياح في الصدر أو ضيق نفس.</li></ul><p><strong>الأطفال والمراهقون</strong><br />لم تختبر سلامة وفعالية العقار&nbsp; CALQUENCE&reg;&nbsp;على الأطفال أو المراهقين. لذا تجنب إعطاء هذا الدواء للأطفال أو&nbsp;المراهقين ممن يقل عمرهم عن 18 عامًا .</p><p><strong>الحمل</strong></p><p>تحدثي إلى طبيبك قبل تناول CALQUENCE&reg;&nbsp;إذا كنتِ حاملاً، أو تعتقدين أنك حامل، أو تنوين الحمل. هذا لأن&nbsp;CALQUENCE&reg;&nbsp;قد يضر بجنينك. إذا كنتِ حاملاً، فينبغي ألا تتناولي&nbsp;&nbsp;CALQUENCE&reg;&nbsp; .يجب أن تتجنبي الحمل أثناء تناول هذا الدواء .</p><p><strong>الرضاعة الطبيعية</strong></p><p>قبل تناول<strong>&nbsp;</strong>CALQUENCE&reg; ،خبري طبيبك إن كنتِ ترضعين. من غير المعروف ما إذا كان&nbsp;&nbsp;CALQUENCE&reg;&nbsp;يتم&nbsp;إفرازه في حليب الأم أم لا . لا تُرضعي طفلكِ خلال العلاج بالعقار&nbsp;CALQUENCE&reg;&nbsp;ولمدة يومين بعد جرعتك النهائية&nbsp;&nbsp;من&nbsp;CALQUENCE&reg; .</p><p><strong>القيادة واستخدام الآلات</strong></p><p>من المستبعد أن يؤثر<strong>&nbsp;&nbsp;&nbsp;</strong>CALQUENCE&reg;&nbsp;على القدرة على القيادة واستخدام الآلات. ومع هذا، إذا شعرت بالدوار أو&nbsp;الضعف أو التعب أثناء تناول&nbsp;CALQUENCE&reg;،&nbsp;فعليك توخي الحذر الشديد عند القيادة أو استخدام الآلات.&nbsp;</p><p><strong>تناول أدوية أخرى</strong><br />أخبر طبيبك والصيدلي إذا كنت تتناول أو تناولت مؤخرًا أي أدوية أخرى، بما في ذلك الأدوية التي حصلت عليها دون وصفة طبية والأدوية العشبية والمكملات.</p><p><strong>قد يجعلك CALQUENCE&reg;&nbsp;تنزف بسهولة أكبر.</strong> يعني هذا أنك يجب أن تُخبر طبيبك إذا كنت تتناول أدوية أخرى تزيد من خطر النزيف. يشمل هذا:&nbsp;</p><ul><li>حمض الأسيتيل ساليسيك ومضادات الالتهاب غير الستيرويدية (NSAIDs)</li><li>الأدوية المستخدمة لمنع تخثر الدم، مثل العلاج المضاد لتكون الصفيحات أو مرققات الدم</li></ul><p>قد تؤثر بعض الأدوية على مستويات&nbsp;CALQUENCE&reg;&nbsp;في جسمك. وقد يؤثر أيضًا عقار&nbsp;CALQUENCE&reg; على&nbsp;طريقة عمل بعض الأدوية الأخرى. أخبر طبيبك إذا كنت تتناول أيًا مما يلي:</p><ul><li>مضادات حيوية تُستخدم لعلاج عدوى بكتيرية (مثل كلاريثرومايسين)</li><li>أدوية لعلاج عدوى فطرية (مثل بوساكونازول، كيتوكونازول، إيتراكونازول، فوريكونازول)</li><li>أدوية تُستخدم لعلاج عدوى فيروس نقص المناعة البشرية(مثل إندينافير)</li><li>أدوية تُستخدم لعلاج التهاب الكبد C(مثل تيلابريفير)</li><li>ريفامبين، مضاد حيوي يستخدم لعلاج عدوى بكتيرية</li><li>أدوية تُستخدم لمنع النوبات أو لعلاج الصرع (مثل كاربامازيبين، فينيتوين)</li><li>نبتة القديس يوحنا، دواء عشبي، يُستخدم لعلاج الاكتئاب على سبيل المثال</li><li>أدوية تُستخدم لتقليل حمض المعدة، مثل مضادات الحموضة (مثل كربونات الكالسيوم)، أو حاصرات مستقبل الهستامين 2 (مثل رانيتيدين أو فاموتيدين)، أو أدوية معينة تُستخدم لعلاج عسر الهضم الحمضي الشديد، مثل مثبطات ضخ البروتون(مثل أوميبرازول)</li><li>ميثوتريكسات، دواء يُستخدم لعلاج اضطرابات المناعة<br />أخبر طبيبك أو الصيدلي إذا كنت تتناول أيٍ من هذه الأدوية أو أي أدوية أخرى. قد لا تكون الأدوية المذكورة هنا هي&nbsp;الوحيدة التي قد تتفاعل مع&nbsp;CALQUENCE&reg;&nbsp;</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>عليك تناول&nbsp;CALQUENCE&reg;&nbsp;&nbsp;دائمًا بحسب توجيهات الطبيب. استشر طبيبك أو الصيدلي إذا كانت تساورك أيّ شكوك.&nbsp;</p><ul><li>الجرعة العادية كبسولة واحدة 100 ملغ مرتان يوميًا. يجب تناول الجرعات بفارق حوالي 12 ساعة .</li><li>ابلع الكبسولة كاملةً مع ماء في نفس الوقت تقريبًا من كل يوم.</li><li>تناول CALQUENCE&reg;&nbsp;مع الطعام أو بدونه.</li><li>لا تمضغ الكبسولات أو تذيبها أو تفتحها.</li><li>تجنب تناول الأدوية المسماة مثبطات ضخ البروتون (مثل أوميبرازول) خلال تناولك عقار&nbsp; CALQUENCE&reg;.</li><li>إذا تناولت دواءً يسمى مضاد حموضة (مثل كربونات الكالسيوم)، فتناول الدواء مضاد الحموضة قبل ساعتين من تناول&nbsp;CALQUENCE&reg;&nbsp;أو بعد تناوله بساعتين.</li><li>إذا تناولت أدوية تسمى حاصرات مستقبل الهستامين 2 (مثل رانيتيدين أو فاموتيدين)، فتناولCALQUENCE&reg;&nbsp;قبل ساعتين من تناول حاصر مستقبل الهستامين 2.</li></ul><p><strong>إذا تناولت جرعة من عقار&nbsp;CALQUENCE&reg;&nbsp;أكثر مما ينبغي</strong></p><p>إذا تناولت جرعة&nbsp;CALQUENCE&reg;&nbsp;أكثر مما ينبغي، فاذهب لزيارة الطبيب أو اذهب إلى أقرب مستشفى فورًا.</p><p><strong>إذا نسيت تناول إحدى الجرعات</strong></p><ul><li>إذا فوتّ جرعة لأقل من 3 ساعاتٍ، فتناول الجرعة الفائتة فورًا. تناول الجرعة التالية في الوقت المعتاد.</li><li>إذا فوتّ جرعة لأكثر من 3 ساعاتٍ، فتخطى الجرعة الفائتة. تناول الجرعة التالية في الوقت المعتاد .</li><li>لا تتناول أي كبسولات CALQUENCE&reg;&nbsp;إضافية لتعويض جرعة فائتة.</li></ul><p><strong>إذا أوقفت تناول&nbsp;CALQUENCE&reg;</strong></p><p>لا توقف تناول&nbsp;CALQUENCE&reg; إلا كما أخبرك الطبيب. إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء،فتحدث إلى طبيبك أو الصيدلي .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>شأن&nbsp;CALQUENCE&reg;&nbsp;شأن جميع الأدوية، يمكن أن يتسبّب في حدوث آثار جانبية ولكنها لا تصيب كل من يتناوله. قد&nbsp;تحدث بعض هذه الآثار الجانبية بدرجات متفاوتة وتكون كما يلي:</p><p><strong>الآثار الجانبية الشائعة جدًا (تصيب أكثر من شخص واحد من كل 10 أشخاص) التي قد تحدث:</strong></p><ul><li>عدوى، تشمل الأعراض حمى أو قشعريرة أو أعراض تشبه أعراض الأنفلونزا</li><li>الصداع</li><li>الإسهال</li><li>التكدُّم</li><li>ألم في العضلات والعظام</li><li>الغثيان</li><li>التعب</li><li>ألم المفاصل</li><li>الطفح الجلدي&nbsp;</li><li>الإمساك&nbsp;</li><li>دوار</li><li>تقيؤ</li><li>ألم في المعدة&nbsp;</li><li>نزيف</li><li>إصابات جديدة بالسرطان&nbsp;</li></ul><p><strong>ظهرت الآثار الجانبية التالية بصورة شديدة الشيوع في اختبارات الدم:</strong></p><ul><li>انخفاض عدد خلايا الدم البيضاء</li><li>انخفاض عدد خلايا الدم الحمراء</li><li>انخفاض عدد الخلايا التي تساعد الدم على التخثر (الصفيحات)</li></ul><p><strong>الآثار الجانبية الشائعة (تصيب شخص واحد من كل 10 أشخاص) التي قد تحدث:</strong></p><ul><li>نزيف الأنف</li><li>سرطان الجلد اللاميلانوما</li><li>وهن أو فقدان الطاقة</li><li>سرعة ضربات القلب، توقف في نبض القلب، نبض ضعيف أو غير منتظم، دوار، الشعور بالإغماء، ألم في<br />الصدر، ضيق التنفس(أعراض الرجفان الأذيني)</li></ul><p><strong>الآثار الجانبية غير الشائعة )تصيب شخص واحد من كل 100 شخص( التي قد تحدث:</strong></p><ul><li>حالة تسمى متلازمة تحلل الورم( TLS)،&nbsp;عندما تكون هناك مستويات غير طبيعية من المواد الكيميائية في&nbsp;الدم ناتجة عن الانهيار السريع للخلايا السرطانية الذي حدث أثناء علاج السرطان وأحيانًا حتى بدون علاج. أعراض&nbsp;TLS عبارة عن تغيرات في وظائف الكلى أو اضطراب ضربات القلب أو نوبات.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>احتفظ بهذا الدواء بعيدًا عن متناول الأطفال وأنظارهم .</li><li>يُحفظ في العبوة الأصلية.</li><li>لا تستخدم&nbsp;CALQUENCE&reg;&nbsp;بعد تاريخ انتهاء الصلاحية (EXP)&nbsp;المدّون على الزجاجة البلاستيك البيضاء&nbsp;والشريط والعلبة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المدوّن.&nbsp;</li><li>لا يستلزم هذا الدواء شروط تخزين خاصة.&nbsp;</li><li>لا تتخلص من الأدوية عبر مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن إجراءات التخلص من الأدوية التي لم تعد تستعملها. ستساعد هذه الإجراءات على حماية البيئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="rtl">المادة الفعالة هي أكالابروتينيب.</li><li dir="rtl">المكونات الأخرى هي كالتالي:&nbsp;<ul><li>محتوى الكبسولة: سيليولوز دقيق التبلور، وثاني أكسيد السيليكون الغرواني، ونشا سبق هيلمته جزئيًا (ذرة)،وستيرات المغنيسيوم (E572)،وغليكولات نشا الصوديوم (النوعA).</li><li>غلاف الكبسولة: غيلاتين، وثاني أكسيد التيتانيوم (E171) ،وأكسيد حديد أصفر&nbsp; (E172)، وFD&amp;C Blue&nbsp; 2&nbsp; (قرمز نيلجي) ( E132)</li><li>حبر الطباعة: شيلاك، وأكسيد حديد أسود(E172)،&nbsp;وغلايكول البروبلين (E1520)، و&nbsp;وهيدروكسيد الأمونيوم.</li></ul></li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>CALQUENCE&reg;&nbsp;هو كبسولة غيلاتينية صلبة بجسم أصفر وغطاء أزرق، موسوم عليها بحبر أسود &quot; ACA 100 mg&quot;&nbsp;</p><p>يتوفر&nbsp;&nbsp;CALQUENCE&reg;&nbsp; في علب كرتون تحتوي على أشرطة&nbsp;&nbsp;10X6 كبسولات.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>حامل ترخيص التسويق<br />AstraZeneca AB<br />SE-151 85 S&ouml;dert&auml;lje<br />Sweden</p><p>&nbsp;</p><p>جهة التصنيع<br />AstraZeneca AB<br />SE-151 85 S&ouml;dert&auml;lje<br />Sweden</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            اكتوبر 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CALQUENCE® (acalabrutinib) 100 mg capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains 100 mg Acalabrutinib. 
For a full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsule, hard
Size 1 hard gelatine capsule with a yellow body and blue cap, marked in black ink with ‘ACA 100 mg’
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CALQUENCE is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.<br />CALQUENCE is indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with CALQUENCE should be initiated and supervised by a physician experienced in the use of anticancer therapies.<br />&nbsp;</p><p><strong>Posology</strong><br /><u><strong>MCL</strong></u><br />The recommended dose of CALQUENCE for the treatment of MCL is 100 mg (1 capsule) twice daily.</p><p><u><strong>CLL</strong></u><br />The recommended dose of CALQUENCE for the treatment of CLL is 100 mg (1 capsule) twice daily, either as monotherapy or in combination with obinutuzumab. Refer to the obinutuzumab prescribing information for recommended obinutuzumab dosing information. (For details of the combination regimen, see section 5.1).</p><p><br />CALQUENCE should be taken orally approximately every twelve hours until disease progression or unacceptable toxicity.</p><p><strong>Missed Dose</strong><br />If a dose of CALQUENCE is missed by more than 3 hours, it should be skipped and the next dose should be taken at its regularly scheduled time. Extra capsules of CALQUENCE should not be taken to make up for a missed dose.</p><p><br /><strong>Dose Adjustments</strong><br /><u>Adverse Reactions</u><br />Recommended dose modifications of CALQUENCE for Grade 3 or greater adverse reactions are provided in Table 1.</p><p><strong>Table 1: Recommended Dose Modifications for Adverse Reactions</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:635px"><tbody><tr><td style="vertical-align:top"><p><strong>Event </strong></p></td><td style="vertical-align:top"><p><strong>Adverse </strong></p><p><strong>Reaction Occurrence </strong></p></td><td style="vertical-align:top"><p><strong>Dose Modification </strong></p><p>(Starting dose = 100 mg approximately every 12 hours)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Grade 3 or greater non- hematologic toxicities,</p><p>&nbsp;</p><p>Grade 3 thrombocytopenia with bleeding,</p><p>&nbsp;</p><p>Grade 4 thrombocytopenia or</p><p>&nbsp;</p><p>Grade 4 neutropenia lasting longer than 7 days</p></td><td style="vertical-align:top"><p>First and Second</p></td><td style="vertical-align:top"><p>Interrupt CALQUENCE.</p><p>Once toxicity has resolved to Grade 1 or baseline level, CALQUENCE therapy may be resumed at 100 mg approximately every 12</p><p>hours.</p></td></tr><tr><td style="vertical-align:top"><p>Third</p></td><td style="vertical-align:top"><p>Interrupt CALQUENCE.</p><p>Once toxicity has resolved to Grade 1 or baseline level, CALQUENCE therapy may be resumed at 100 mg daily.</p></td></tr><tr><td style="vertical-align:top"><p>Fourth</p></td><td style="vertical-align:top"><p>Discontinue CALQUENCE.</p></td></tr></tbody></table><p>Adverse reactions graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.</p><p><u>Dose Modifications for Use with CYP3A Inhibitors or Inducers</u></p><p><br />Recommended dose modifications are described below [see interaction with other medicinal products and other forms of interaction (4.5)].</p><table border="1" cellspacing="0" cellpadding="0" style="width:650px"><tbody><tr><td style="vertical-align:top"><p><strong>CYP3A </strong></p></td><td style="vertical-align:top"><p><strong>Co-administered Drug </strong></p></td><td style="vertical-align:top"><p><strong>Recommended CALQUENCE use </strong></p></td></tr><tr><td style="vertical-align:top"><p>Inhibition</p></td><td style="vertical-align:top"><p>Strong CYP3A inhibitor</p></td><td style="vertical-align:top"><p>Consider alternative therapies to strong CYP3A inhibitors. monitor patients closely for adverse reactions if taking strong CYP3A inhibitors.</p></td></tr><tr><td style="vertical-align:top"><p>Induction</p></td><td style="vertical-align:top"><p>Strong CYP3A inducers</p></td><td style="vertical-align:top"><p>Consider alternative therapies to strong CYP3A inducers. If these inducers cannot be</p><p>avoided, increase CALQUENCE</p><p>dose to 200 mg approximately every 12 hours</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Concomitant Use with Gastric Acid Reducing Agents</strong><br /><em>Proton Pump Inhibitors: Avoid concomitant use [see interaction with other medicinal products and other forms of interaction (4.5)].<br />H2-Receptor Antagonists: Take CALQUENCE 2 hours before taking a H2-receptor antagonist [see interaction with other medicinal products and other forms of interaction (4.5)].Antacids: Separate dosing by at least 2 hours [see interaction with other medicinal products and other forms of interaction (4.5)</em></p><p><strong>Method of Administration</strong><br />Advise patients to swallow capsule whole with water at approximately the same time each day. Advise patients not to open, break, chew, or dissolve the capsules. CALQUENCE may be taken with or without food.</p><p><br /><strong>Special patient populations</strong><br /><em>Elderly (&ge; 65 years)</em><br />No dose adjustment is necessary based on age (see section 5.2).</p><p><em>Renal Impairment</em><br />No dose adjustment is recommended in patients with mild to moderate renal impairment (eGFR greater than or equal to 30 mL/min/1.73m2 as estimated by MDRD (modification of diet in renal disease equation)). The pharmacokinetics and safety of CALQUENCE in patients with severe renal impairment (eGFR less than 29 mL/min/1.73m2) or end-stage renal disease have not been studied (see section 5.2).</p><p><br /><em>Hepatic Impairment</em><br />No dose adjustment is recommended in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B, or total bilirubin between 1.5-3 times the upper limit of normal [ULN] and any AST). It is not recommended to administer CALQUENCE in patients with severe hepatic impairment (Child-Pugh C or total bilirubin &gt; 3 times ULN and any AST) (see section 5.2).</p><p><u><em>Severe Cardiac Disease</em><br />Patients with severe cardiovascular disease were excluded from CALQUENCE clinical studies.</u></p><p><br /><em>Paediatric and adolescents</em><br />The safety and efficacy of CALQUENCE in children and adolescents aged less than 18 years have not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                None.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Haemorrhage</strong><br />Fatal and serious hemorrhagic events have occurred in patients with hematologic malignancies treated with CALQUENCE. Major hemorrhage (serious or Grade 3 or higher bleeding or any central nervous system bleeding) occurred in 3.0% of patients, with fatal hemorrhage occurring in 0.1% of 1029 patients exposed to CALQUENCE in clinical trials. Bleeding events of any grade, excluding bruising and petechiae, occurred in 22% of patients.</p><p>Use of antithrombotic agents concomitantly with CALQUENCE may further increase the risk of hemorrhage. In clinical trials, major hemorrhage occurred in 2.7% of patients taking CALQUENCE without antithrombotic agents and 3.6% of patients taking CALQUENCE with antithrombotic agents. Consider the risks and benefits of antithrombotic agents when co-administered with CALQUENCE. Monitor patients for signs of bleeding.</p><p>Consider the benefit-risk of withholding CALQUENCE for at least 3 days pre- and post-surgery.</p><p>&nbsp;</p><p><strong>Infections</strong><br />Fatal and serious infections, including opportunistic infections, have occurred in patients with hematologic malignancies treated with CALQUENCE.<br />Serious or Grade 3 or higher infections (bacterial, viral, or fungal) occurred in 19% of 1029 patients exposed to CALQUENCE in clinical trials, most often due to respiratory tract infections (11% of all patients, including pneumonia in 6%). These infections predominantly occurred in the absence of Grade 3 or 4 neutropenia, with neutropenic infection reported in 1.9% of all patients. Opportunistic infections in recipients of CALQUENCE have included, but are not limited to, hepatitis B virus reactivation, fungal pneumonia, Pneumocystis jiroveci pneumonia, Epstein-Barr virus reactivation, cytomegalovirus, and progressive multifocal leukoencephalopathy (PML). Consider prophylaxis in patients who are at increased risk for opportunistic infections. Monitor patients for signs and symptoms of infection and treat promptly.</p><p>&nbsp;</p><p><strong>Cytopenias</strong><br />Grade 3 or 4 cytopenias, including neutropenia (23%), anemia (8%), thrombocytopenia (7%), and lymphopenia (7%), developed in patients with hematologic malignancies treated with CALQUENCE. Grade 4 neutropenia developed in 12% of patients. Monitor complete blood counts regularly during treatment. Interrupt treatment, reduce the dose, or discontinue treatment as warranted [see Posology and method of adminstration (4.2)].<br /><strong>Second Primary Malignancies</strong><br />Second primary malignancies, including skin cancers and other solid tumors, occurred in 12% of 1029 patients exposed to CALQUENCE in clinical trials. The most frequent second primary malignancy was skin cancer, reported in 6% of patients. Monitor patients for skin cancers and advise protection from sun exposure.</p><p>&nbsp;</p><p><strong>Atrial Fibrillation and Flutter</strong><br />Grade 3 atrial fibrillation or flutter occurred in 1.1% of 1029 patients treated with CALQUENCE, with all grades of atrial fibrillation or flutter reported in 4.1% of all patients. The risk may be increased in patients with cardiac risk factors, hypertension, previous arrhythmias, and acute infection. Monitor for symptoms of arrhythmia (e.g., palpitations, dizziness, syncope, dyspnea) and manage as appropriate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Active substances whose plasma concentrations may be altered by CALQUENCE</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Strong CYP3A Inhibitors</p></td></tr><tr><td><p><em>Clinical Impact</em></p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Co-administration of CALQUENCE with a strong CYP3A inhibitor (itraconazole) increased acalabrutinib plasma concentrations <em>[see pharmacokinetic properties (5.2) ]</em>.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased acalabrutinib concentrations may result in increased toxicity.</p><p>&nbsp;</p></td></tr><tr><td><p><em>Prevention or Management</em></p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Consider alternative therapies that do not strongly inhibit CYP3A activity. Patients taking strong CYP3A inhibitors (e.g., ketoconazole, conivaptan, clarithromycin, indinavir, itraconazole, ritonavir, telaprevir, posaconazole, voriconazole) with CALQUENCE should be monitored more closely for adverse reactions. <em>[see posology and method of administration (4.2)]. </em></p><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Active substances that may decrease acalabrutinib plasma concentrations</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Strong CYP3A Inducers</p></td></tr><tr><td><p><em>Clinical Impact</em></p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&bull; Co-administration of CALQUENCE with a strong CYP3A inducer (rifampin) decreased acalabrutinib plasma concentrations <em>[see pharmacokinetic properties (5.2)]</em>.</p><p>&bull; Decreased acalabrutinib concentrations may reduce CALQUENCE &nbsp;activity.</p></td></tr><tr><td><p><em>Prevention or Management</em></p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Consider alternative therapies to strong inducers of CYP3A activity (e.g., phenytoin, rifampin, carbamazepine). Avoid St. John&rsquo;s wort which may unpredictably decrease acalabrutinib plasma concentrations. . If a strong CYP3A inducer cannot be avoided, increase the CALQUENCE dose to 200 mg twice daily.</p><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Gastric Acid Reducing Agents</p></td></tr><tr><td><p><em>Clinical Impact</em></p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Co-administration of CALQUENCE with a proton pump inhibitor, H2- receptor antagonist, or antacid may decrease acalabrutinib plasma concentrations <em>[see pharmacokinetic properties (5.2)]</em>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased acalabrutinib concentrations may reduce CALQUENCE activity.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If treatment with a gastric acid reducing agent is required, consider using a H2-receptor antagonist (e.g., ranitidine or famotidine) or an antacid (e.g., calcium carbonate).</p><p>&nbsp;</p></td></tr><tr><td rowspan="3"><p><em>Prevention or Management</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Antacids</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Separate dosing by at least 2 hours <em>[see posology and method of administration (4.2)]. </em></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>H2-receptor antagonists</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Take CALQUENCE 2 hours before taking the H2-receptor antagonist <em>[see posology and method of administration (4.2)]. </em></p></td></tr><tr><td style="vertical-align:top"><p>Proton pump inhibitors</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Avoid co-administration. Due to the long-lasting effect of proton pump inhibitors, separation of doses may not eliminate the interaction with CALQUENCE</p></td></tr></tbody></table><p><strong>Active substances whose plasma concentrations may be altered by CALQUENCE</strong></p><p><em>CYP3A Substrates</em></p><p>Based on in vitro data and PBPK modeling, no interaction with CYP substrates is expected at clinically relevant concentrations (see section 5.2).</p><p>Effects of Acalabrutinib and its active metabolite, ACP-5862, on Drug Transport Systems</p><p>Acalabrutinib may increase exposure to co-administered Breast Cancer Resistance Protein (BCRP) substrates (e.g., methotrexate) by inhibition of intestinal BCRP. (see section 5.2)<br /><u>ACP-5862 may increase exposure to co-administered MATE1 substrates (e.g., metformin) by inhibition of MATE1 (see section 5.2).</u></p><p><strong>Effect of food on acalabrutinib</strong></p><p>In healthy subjects, administration of a single 75 mg dose of acalabrutinib (0.75 times the approved recommended single dose) with a high-fat, high-calorie meal (approximately 918 calories, 59 grams carbohydrate, 59 grams fat, and 39 grams protein) did not affect the mean AUC as compared to dosing under fasted conditions. Resulting Cmax decreased by 73% and Tmax was delayed 1-2 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong><br /><u>Risk Summary</u></p><p>Based on findings in animals, CALQUENCE may cause fetal harm when administered to a pregnant woman. There are no available data in pregnant women to inform the drug-associated risk. In animal reproduction studies, administration of acalabrutinib to pregnant rabbits during organogenesis resulted in reduced fetal growth at maternal exposures (AUC) approximately 4 times exposures in patients at the recommended dose of 100 mg twice daily (see Data). Advise pregnant women of the potential risk to a fetus.</p><p>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</p><p><u>Data</u><br /><em>Animal Data</em></p><p>In a combined fertility and embryo-fetal development study in female rats, acalabrutinib was administered orally at doses up to 200 mg/kg/day starting 14 days prior to mating through gestational day [GD] 17. No effects on embryo-fetal development and survival were observed. The AUC at 200 mg/kg/day in pregnant rats was approximately 16-times the AUC in patients at the recommended dose of 100 mg twice daily. The presence of acalabrutinib and its active metabolite were confirmed in fetal rat plasma.</p><p>In an embryo-fetal development study in rabbits, pregnant animals were administered acalabrutinib orally at doses up to 200 mg/kg/day during the period of organogenesis (from GD 6-18). Administration of acalabrutinib at doses &ge; 100 mg/kg/day produced maternal toxicity and 100 mg/kg/day resulted in decreased fetal body weights and delayed skeletal ossification. The AUC at 100 mg/kg/day in pregnant rabbits was approximately 4-times the AUC in patients at 100 mg twice daily. Dystocia was observed in a rat study involving dosing animals from implantation throughout gestation, parturition and lactation at exposures &gt; 2.3-times the human AUC at the recommended dose (see section 5.3)</p><p>&nbsp;</p><p><strong>Lactation</strong><br /><u>Risk Summary</u></p><p>No data are available regarding the presence of acalabrutinib or its active metabolite in human milk, its effects on the breastfed child, or on milk production. Acalabrutinib and its active metabolite were present in the milk of lactating rats. Due to the potential for adverse reactions in a breastfed child from CALQUENCE, advise lactating women not to breastfeed while taking CALQUENCE and for at least 2 days after the final dose.</p><p>&nbsp;</p><p><strong>Fertility</strong><br />There are no data on the effect of Calquence on human fertility. In a non-clinical study of acalabrutinib in male and female rats, no adverse effects on fertility parameters were observed (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CALQUENCE has no or negligible influence on the ability to drive and use machines. However, during treatment with acalabrutinib fatigue and dizziness have been reported and patients who experience these symptoms should observe caution when driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Overall Summary of Adverse Drug Reactions</strong></p><p>The overall safety profile of acalabrutinib is based on pooled data from 1040 patients with haematologic malignancies receiving acalabrutinib monotherapy.</p><p>The most common (&ge; 20%) adverse drug reactions (ADRs) of any grade reported in patients receiving acalabrutinib were infection, headache, diarrhoea, bruising, musculoskeletal pain, nausea, fatigue, and rash.</p><p>The most commonly reported (&ge; 5%) Grade &ge; 3 adverse drug reactions were infection (17.6%), leuokopenia (16.2%), neutropenia (14.2%) and anaemia (7.8%). Dose reductions due to adverse events were reported in 4.2% of patients. Discontinuation due to adverse events were reported in 9.3% of the patients. The median dose intensity was 98.7%.</p><p><strong>Tabulated list of adverse reactions</strong></p><p>The following adverse drug reactions (ADRs) have been identified in clinical studies with patients receiving CALQUENCE monotherapy as treatment for haematological malignancies. The median duration of acalabrutinib monotherapy treatment across the pooled dataset was 24.6months.</p><p>Adverse drug reactions are listed according to system organ class (SOC) in MedDRA. Within each system organ class, the adverse drug reactions are sorted by frequency, with the most frequent reactions first. In addition, the corresponding frequency category for each ADR is based on the CIOMS III convention and is defined as: very common (&ge;1/10); common (&gt;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1000); very rare (&lt;1/10,000); not known (cannot be estimated from available data).</p><p><strong>Table 3. Adverse drug reactions* of patients with haematological malignancies treated with acalabrutinib monotherapy (n=1040)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:721px"><tbody><tr><td><p><strong>MedDRA SOC</strong></p></td><td><p><strong>MedDRA Term</strong></p></td><td style="width:194px"><p><strong>CIOMS descriptor/ Overall Frequency (all CTCAE grades)</strong></p></td><td style="width:111px"><p><strong>Frequency of CTCAE Grade &ge; 3&dagger;</strong></p></td></tr><tr><td rowspan="4"><p><strong>Blood and lymphatic system disorders</strong></p><p><strong>&nbsp;</strong></p></td><td><p>Leukopenia&dagger;</p></td><td style="width:194px"><p>Very common (16.2%)</p></td><td style="width:111px"><p>14%</p></td></tr><tr><td><p>Neutropenia</p></td><td style="width:194px"><p>Very common (15.7%)</p></td><td style="width:111px"><p>14%</p></td></tr><tr><td><p>Anaemia</p></td><td style="width:194px"><p>Very common (13.8%)</p></td><td style="width:111px"><p>8%</p></td></tr><tr><td><p>Thrombocytopenia</p></td><td style="width:194px"><p>Common (8.9%)</p></td><td style="width:111px"><p>4.8%</p></td></tr><tr><td><p><strong>Cardiac disorders</strong></p></td><td><p>Atrial Fibrillation/Flutter&dagger;</p></td><td style="width:194px"><p>Common (4.4%)</p></td><td style="width:111px"><p>1.3%</p></td></tr><tr><td rowspan="2"><p><strong>Nervous system disorders</strong></p><p><strong>&nbsp;</strong></p></td><td><p>Headache</p></td><td style="width:194px"><p>Very common (37.8%)</p></td><td style="width:111px"><p>1.1%</p></td></tr><tr><td><p>Dizziness</p></td><td style="width:194px"><p>Very common (13.4%)</p></td><td style="width:111px"><p>0.2%</p></td></tr><tr><td><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td><p>Epistaxis</p></td><td style="width:194px"><p>Common (7%)</p></td><td style="width:111px"><p>0.3%</p></td></tr><tr><td rowspan="5"><p><strong>Gastrointestinal disorders</strong></p><p><strong>&nbsp;</strong></p></td><td><p>Diarrhoea</p></td><td style="width:194px"><p>Very common (36.7%)</p></td><td style="width:111px"><p>2.6%</p></td></tr><tr><td><p>Nausea</p></td><td style="width:194px"><p>Very common (21.7%)</p></td><td style="width:111px"><p>1.2%</p></td></tr><tr><td><p>Constipation</p></td><td style="width:194px"><p>Very common (14.5%)</p></td><td style="width:111px"><p>0.1%</p></td></tr><tr><td><p>Abdominal pain&dagger;</p></td><td style="width:194px"><p>Very common (12.5%)</p></td><td style="width:111px"><p>1%</p></td></tr><tr><td><p>Vomiting</p></td><td style="width:194px"><p>Very common (13.3%)</p></td><td style="width:111px"><p>0.9%</p></td></tr><tr><td rowspan="2"><p><strong>General disorders and administration site conditions</strong></p><p><strong>&nbsp;</strong></p></td><td><p>Fatigue</p></td><td style="width:194px"><p>Very common (21.3%)</p></td><td style="width:111px"><p>2%</p></td></tr><tr><td><p>Asthenia</p></td><td style="width:194px"><p>Common (5.3%)</p></td><td style="width:111px"><p>0.8%</p></td></tr><tr><td><p><strong>Metabolism and nutrition disorders</strong></p></td><td><p>Tumour Lysis Syndrome&plusmn;</p></td><td style="width:194px"><p>Uncommon (0.5%)</p></td><td style="width:111px"><p>0.4%</p></td></tr><tr><td rowspan="2"><p><strong>Musculoskeletal and connective tissue disorders</strong></p><p><strong>&nbsp;</strong></p></td><td><p>Arthralgia</p></td><td style="width:194px"><p>Very common (19.1%)</p></td><td style="width:111px"><p>0.7%</p></td></tr><tr><td><p>Musculoskeletal Pain&dagger;</p></td><td style="width:194px"><p>Very common (33.1%)</p></td><td style="width:111px"><p>1.5%</p></td></tr><tr><td><p><strong>Infections and Infestations</strong></p></td><td><p>Infection&dagger;</p></td><td style="width:194px"><p>Very common (66.7%)</p></td><td style="width:111px"><p>18%</p></td></tr><tr><td rowspan="3"><p><strong>&nbsp;</strong></p><p><strong>Neoplasms benign, malignant and unspecified</strong></p><p><strong>&nbsp;</strong></p></td><td><p>Second Primary Malignancy<strong>&dagger;</strong></p></td><td style="width:194px"><p>Very common (12.2%)</p></td><td style="width:111px"><p>4.1%</p></td></tr><tr><td><p>SPM excluding non-melanoma skin<strong>&dagger;</strong></p></td><td style="width:194px"><p>Common (6.5%)</p></td><td style="width:111px"><p>3.8%</p></td></tr><tr><td><p>Non-Melanoma Skin Malignancy<strong>&dagger;</strong></p></td><td style="width:194px"><p>Common (6.6%)</p></td><td style="width:111px"><p>0.5%</p></td></tr><tr><td rowspan="2"><p><strong>Skin and subcutaneous tissue disorders</strong></p><p><strong>&nbsp;</strong></p></td><td><p>Bruising&dagger;</p></td><td style="width:194px"><p>Very common (34.1%)</p></td><td style="width:111px"><p>-</p></td></tr><tr><td><p>Rash&dagger;</p></td><td style="width:194px"><p>Very common (20.3%)</p></td><td style="width:111px"><p>0.6%</p></td></tr><tr><td><p><strong>Vascular disorders</strong></p></td><td><p>Hemorrhage/Hematoma&dagger;</p></td><td style="width:194px"><p>Very common (12.6%)</p></td><td style="width:111px"><p>1.8%</p></td></tr></tbody></table><p>*Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.<br />&dagger;Includes multiple ADR term<br />&plusmn;One case of drug-induced Tumour Lysis Syndrome was observed in acalabrutinib arm in the ASCEND Study</p><p>&nbsp;</p><p><strong>Table 4. Treatment-emergent haematological laboratory abnormalities for acalabrutinib monotherapy (n=1040)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:749px"><tbody><tr><td><p><strong>MedDRA SOC</strong></p></td><td><p><strong>MedDRA Term</strong></p></td><td><p><strong>CIOMS descriptor/ Overall Frequency (all CTCAE Grades)</strong></p></td><td style="width:100px"><p><strong>Frequency of CTCAE Grade 3-4</strong></p></td></tr><tr><td rowspan="3"><p><strong>Investigations</strong></p><p>(findings based on test results presented as CTCAE grade shifts)</p></td><td><p>Absolute neutrophil count decreased</p></td><td><p>Very common (41.8%)</p></td><td style="width:100px"><p>20.7%</p></td></tr><tr><td><p>Haemoglobin decreased</p></td><td><p>Very common (42.6%)</p></td><td style="width:100px"><p>10.1%</p></td></tr><tr><td><p>Platelets decreased</p></td><td><p>Very common (31.1%)</p></td><td style="width:100px"><p>6.9%</p></td></tr></tbody></table><p>Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.</p><p>&nbsp;</p><p><strong>Special populations</strong><br /><em>Elderly</em><br /><u>Of the 1040</u> patients in clinical trials of CALQUENCE <u>monotherapy, 41%</u> were&nbsp;<u>greater than</u> 65 years of age <u>and less than 75 years of age,</u> and 22% were 75 years of age or older. No clinically relevant differences in safety or efficacy were observed between patients &ge; 65 years and younger.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment for acalabrutinib overdose and symptoms of overdose have not been established. In the event of an overdose, patients must be closely monitored for signs or symptoms of adverse reactions and appropriate symptomatic treatment instituted.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: acalabrutinib , ATC code (L01EL02)</p><p><strong>Mechanism of action</strong></p><p>Acalabrutinib is a small-molecule inhibitor of BTK. Acalabrutinib and its active metabolite, ACP-5862, form a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. In nonclinical<br />studies, acalabrutinib inhibited BTK-mediated activation of downstream signaling proteins CD86 and CD69 and inhibited malignant B-cell proliferation and. growth in mouse xenograft models.</p><p><strong>Pharmacodynamic effects</strong><br />In patients with B-cell malignancies dosed with 100 mg twice daily, median steady state BTK occupancy of &ge; 95% in peripheral blood was maintained over 12 hours, resulting in inactivation of BTK throughout the recommended dosing interval.</p><p><u>Cardiac Electrophysiology</u><br />The effect of acalabrutinib on the QTc interval was evaluated in a randomized, double-blind, double-dummy, placebo- and positive-controlled, 4-way crossover thorough QTc study in 48 healthy adult subjects. Administration of a single dose of acalabrutinib that is the 4-fold maximum recommended single dose did not prolong the QTc interval to any clinically relevant extent (i.e., &ge; 10 ms).</p><p>&nbsp;</p><p><strong>Clinical efficacy and safety in patients</strong><br /><strong>MCL</strong><br />The safety and efficacy of CALQUENCE in MCL were evaluated in an open-label, multi-centre, single-arm Phase 2 study (ACE-LY-004) of 124 previously treated patients. All patients received CALQUENCE 100 mg orally twice daily until disease progression or unacceptable toxicity. The trial did not include patients who received prior treatment with BTK inhibitors. The primary endpoint was investigator-assessed overall response rate (ORR) per the Lugano classification for non-Hodgkin&rsquo;s lymphoma (NHL). Duration of Response (DoR) was an additional outcome measure. Efficacy results are presented in Table5.</p><p>The median age was 68 (range 42 to 90) years, 79.8% were male and 74.2% were Caucasian. At baseline, 92.8% of patients had an ECOG performance status of 0 or 1. The median time since diagnosis was 46.3 months and the median number of prior treatments was 2 (range 1 to 5), including 17.7% with prior stem cell transplant. The most common prior regimens were CHOP- based (51.6%) and ARA-C (33.9%). At baseline, 37.1% of patients had at least one tumour with a longest diameter &ge; 5 cm, 72.6% had extra nodal involvement including 50.8% with bone marrow involvement. The simplified MIPI score (which includes age, ECOG score, and baseline lactate dehydrogenase and white cell count) was intermediate in 43.5% and high in 16.9% of patients.]</p><p><strong>Table 5. Overall Response Rate and Duration of Response in (ACE-LY-004) Patients with MCL</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:650px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Investigator Assessed N=124</strong></p></td><td style="vertical-align:top"><p><strong>Independent Review Committee (IRC) Assessed </strong></p><p><strong>N=124</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>n (%) (95% CI*)</p></td><td style="vertical-align:top"><p>n (%) (95% CI*)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Overall Response Rate (ORR)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall Response Rate</p></td><td style="vertical-align:top"><p>100 (80.6%) (72.6, 87.2)</p></td><td style="vertical-align:top"><p>99 (79.8%) (71.7, 86.5)</p></td></tr><tr><td style="vertical-align:top"><p>Complete Response</p></td><td style="vertical-align:top"><p>49 (39.5%) (30.9, 48.7)</p></td><td style="vertical-align:top"><p>49 (39.5%) (30.9, 48.7)</p></td></tr><tr><td style="vertical-align:top"><p>Partial Response</p></td><td style="vertical-align:top"><p>51 (41.1%) (32.4, 50.3)</p></td><td style="vertical-align:top"><p>50 (40.3%) (31.6, 49.5)</p></td></tr><tr><td style="vertical-align:top"><p>Stable Disease</p></td><td style="vertical-align:top"><p>11 (8.9%) (4.5, 15.3)</p></td><td style="vertical-align:top"><p>9 (7.3%) (3.4, 13.3)</p></td></tr><tr><td style="vertical-align:top"><p>Progressive Disease</p></td><td style="vertical-align:top"><p>10 (8.1%) (3.9, 14.3)</p></td><td style="vertical-align:top"><p>11 (8.9%) (4.9, 15.3)</p></td></tr><tr><td style="vertical-align:top"><p>Non-Evaluable&dagger;</p></td><td style="vertical-align:top"><p>3 (2.4%) (0.5, 6.9)</p></td><td style="vertical-align:top"><p>5 (4.0%) (1.3, 9.2)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Duration of Response (DoR)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median (months)</p></td><td style="vertical-align:top"><p>NR (13.5, NR)</p></td><td style="vertical-align:top"><p>NR (14.8, NR)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Landmark DOR</strong></p></td></tr><tr><td style="vertical-align:top"><p>12 months estimate (%) (95% CI)</p></td><td style="vertical-align:top"><p>72.1 (61.6, 80.2)</p></td><td style="vertical-align:top"><p>72.3 (61.9, 80.2)</p></td></tr><tr><td style="vertical-align:top"><p>18 months estimate (%) (95% CI)</p></td><td style="vertical-align:top"><p>63.3 (49.4, 74.3)</p></td><td style="vertical-align:top"><p>56.0 (38.2, 70.6)</p></td></tr></tbody></table><p>CI=Confidence Interval; NR = Not Reached<br />*95% exact binomial confidence interval.<br />&dagger;Includes subjects without any adequate post-baseline disease assessment.</p><p>&nbsp;</p><p>Based on investigator assessment, 92% of responders achieved a response by cycle 2, with a median time to documented response of 1.9 months. The median DoR had not been reached at<br />15.2 months median follow-up from treatment initiation. Seventy two percent (72%) of patients had an ongoing response at 12 months per Kaplan-Meier estimate. The ORR was consistent across all pre-specified subgroups including age, performance status, disease stage, and number of prior therapies.</p><p><u><strong>CLL</strong><br />Patients with Previously Untreated CLL</u></p><p><u>The safety and efficacy of CALQUENCE in previously untreated CLL were evaluated in a randomised, multi-centre, open-label Phase 3 study (ELEVATE-TN) of 535 patients. Patients received CALQUENCE plus obinutuzumab, CALQUENCE monotherapy, or obinutuzumab plus chlorambucil. Patients 65 years of age or older or between 18 and 65 years of age with coexisting medical conditions were included in ELEVATE-TN. The trial also allowed patients to receive antithrombotic agents other than warfarin or equivalent vitamin K antagonists.</u></p><p><br /><u>Patients were randomised in a 1:1:1 ratio into 3 arms to receive</u></p><ul><li><u>CALQUENCE plus obinutuzumab (CALQUENCE+G): CALQUENCE 100 mg was administered twice daily starting on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Obinutuzumab was administered starting on Cycle 2 Day 1 for a maximum of 6 treatment cycles. Obinutuzumab 1000 mg was administered on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of Cycle 2 followed by 1000 mg on Day 1 of Cycles 3 up to 7. Each cycle was 28 days.</u></li><li><u>CALQUENCE monotherapy: CALQUENCE 100 mg was administered twice daily until disease progression or unacceptable toxicity.</u></li><li><u>Obinutuzumab plus chlorambucil (GClb): Obinutuzumab and chlorambucil were administered for a maximum of 6 treatment cycles. Obinutuzumab 1000 mg was administered on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of Cycle 1 followed by 1000 mg on Day 1 of Cycles 2 up to 6. Chlorambucil 0.5 mg/kg was administered on Days 1 and 15 of Cycles 1 up to 6. Each cycle was 28 days.</u></li></ul><p><u>Patients were stratified by 17p deletion mutation status (presence versus absence), ECOG performance status (0 or 1 versus 2) and geographic region (North America and Western Europe versus Other). After confirmed disease progression, 45 patients randomised on the GClb arm crossed over to CALQUENCE monotherapy.</u><br />&nbsp;</p><p><u>Table 6 summarizes the baseline demographics and disease characteristics of the study population.</u></p><p><strong>Table 6. Baseline Patient Characteristics in (ELEVATE-TN) Patients with Previously Untreated CLL</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Characteristic</strong></p></td><td><p><strong>CALQUENCE plus obinutuzumab</strong></p><p><strong>N=179</strong></p></td><td><p><strong>CALQUENCE Monotherapy</strong></p><p><strong>N=179</strong></p></td><td><p><strong>Obinutuzumab plus Chlorambucil</strong></p><p><strong>N=177</strong></p></td></tr><tr><td><p>Age, years; median (range)</p></td><td><p>70 (41-88)</p></td><td><p>70 (44-87)</p></td><td><p>71 (46-91)</p></td></tr><tr><td><p>Male; %</p></td><td><p>62</p></td><td><p>62</p></td><td><p>59.9</p></td></tr><tr><td><p>Caucasian; %</p></td><td><p>91.6</p></td><td><p>95</p></td><td><p>93.2</p></td></tr><tr><td><p>ECOG performance status 0-1; %</p></td><td><p>94.4</p></td><td><p>92.2</p></td><td><p>94.4</p></td></tr><tr><td><p>Median time from diagnosis (months)</p></td><td><p>30.5</p></td><td><p>24.4</p></td><td><p>30.7</p></td></tr><tr><td><p>Bulky disease with nodes &ge; 5 cm; %</p></td><td><p>25.7</p></td><td><p>38</p></td><td><p>31.1</p></td></tr><tr><td style="vertical-align:top"><p>17p deletion</p><p>&nbsp;</p><p>11q deletion</p><p>&nbsp;</p><p>TP53 mutation</p><p>&nbsp;</p><p>Unmutated IGHV</p><p>&nbsp;</p><p>Complex karyotype (&ge; 3 abnormalities)</p><p>&nbsp;</p></td><td><p>9.5</p><p>&nbsp;</p><p>17.3</p><p>&nbsp;</p><p>11.7</p><p>&nbsp;</p><p>57.5</p><p>&nbsp;</p><p>16.2</p><p>&nbsp;</p></td><td><p>8.9</p><p>&nbsp;</p><p>17.3</p><p>&nbsp;</p><p>10.6</p><p>&nbsp;</p><p>66.5</p><p>&nbsp;</p><p>17.3</p><p>&nbsp;</p></td><td><p>9</p><p>&nbsp;</p><p>18.6</p><p>&nbsp;</p><p>11.9</p><p>&nbsp;</p><p>65.5</p><p>&nbsp;</p><p>18.1</p><p>&nbsp;</p></td></tr><tr><td colspan="4"><p>Rai stage; %</p></td></tr><tr><td style="vertical-align:top"><p>0</p><p>I</p><p>II</p><p>III</p><p>IV</p><p>&nbsp;</p></td><td><p>1.7</p><p>30.2</p><p>20.1</p><p>26.8</p><p>21.2</p><p>&nbsp;</p></td><td><p>0</p><p>26.8</p><p>24.6</p><p>27.9</p><p>20.7</p><p>&nbsp;</p></td><td><p>0.6</p><p>28.2</p><p>27.1</p><p>22.6</p><p>21.5</p><p>&nbsp;</p></td></tr></tbody></table><p><u>The primary endpoint was progression-free survival (PFS) as assessed by an Independent Review Committee (IRC) per International Workshop on Chronic Lymphocytic Leukaemia (IWCLL) 2008 criteria with incorporation of the clarification for treatment-related lymphocytosis (Cheson 2012). With a median follow-up of 28.3 months, PFS by IRC indicated a 90% statistically significant reduction in the risk of disease progression or death for previously untreated CLL patients in the CALQUENCE+G arm compared to the GClb arm. At the time of analysis, median overall survival had not been reached in any arm with a total of 37 deaths: 9 (5%) in the CALQUENCE+G arm, 11 (6.1%) in the CALQUENCE monotherapy arm, and 17 (9.6%) in the GClb arm. Efficacy results are presented in Table 7. The Kaplan-Meier curves for PFS are shown in Figure 1.</u></p><p><strong>Table 7. Efficacy Results in (ELEVATE-TN) Patients with CLL</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:741px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>CALQUENCE plus obinutuzumab </strong></p><p><strong>N=179 </strong></p></td><td style="vertical-align:top"><p><strong>CALQUENCE Monotherapy </strong></p><p><strong>N=179 </strong></p></td><td style="vertical-align:top; width:184px"><p><strong>Obinutuzumab plus Chlorambucil </strong></p><p><strong>N=177 </strong></p></td></tr><tr><td colspan="4" style="vertical-align:top; width:740px"><p><strong>Progression-Free Survival</strong><strong>* </strong></p></td></tr><tr><td><p>Number of events (%)</p></td><td><p>14 (7.8%)</p></td><td><p>26 (14.5%)</p></td><td style="width:184px"><p>93 (52.5%)</p></td></tr><tr><td><p>PD, n (%)</p></td><td><p>9 (5%)</p></td><td><p>20 (11.2%)</p></td><td style="width:184px"><p>82 (46.3%)</p></td></tr><tr><td><p>Death events (%)</p></td><td><p>5 (2.8%)</p></td><td><p>6 (3.4%)</p></td><td style="width:184px"><p>11 (6.2%)</p></td></tr><tr><td><p>Median (95% CI), months</p></td><td><p>NR</p></td><td><p>NR (34.2, NR)</p></td><td style="width:184px"><p>22.6 (20.2, 27.6)</p></td></tr><tr><td><p>HR&dagger; (95% CI)</p></td><td><p>0.10 (0.06, 0.17)</p></td><td><p>0.20 (0.13, 0.30)</p></td><td style="width:184px"><p>-</p></td></tr><tr><td><p>P-value</p></td><td><p>&lt; 0.0001</p></td><td><p>&lt; 0.0001</p></td><td style="width:184px"><p>-</p></td></tr><tr><td><p>24 months estimate, % (95% CI)</p></td><td><p>92.7 (87.4, 95.8)</p></td><td><p>87.3 (80.9, 91.7)</p></td><td style="width:184px"><p>46.7 (38.5, 54.6)</p></td></tr><tr><td colspan="4" style="width:740px"><p><strong>Overall Response Rate</strong><strong>* </strong><strong>(CR + CRi + nPR + PR) </strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR, n (%)</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>168 (93.9)</p><p>(89.3, 96.5)</p></td><td style="vertical-align:top"><p>153 (85.5)</p><p>(79.6, 89.9)</p></td><td style="vertical-align:top; width:184px"><p>139 (78.5)</p><p>(71.9, 83.9)</p></td></tr><tr><td style="vertical-align:top"><p>P-value</p></td><td style="vertical-align:top"><p>&lt; 0.0001</p></td><td style="vertical-align:top"><p>0.0763</p></td><td style="vertical-align:top; width:184px"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>CR, n (%)</p></td><td style="vertical-align:top"><p>23 (12.8)</p></td><td style="vertical-align:top"><p>1 (0.6)</p></td><td style="vertical-align:top; width:184px"><p>8 (4.5)</p></td></tr><tr><td style="vertical-align:top"><p>CRi, n (%)</p></td><td style="vertical-align:top"><p>1 (0.6)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top; width:184px"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>nPR, n (%)</p></td><td style="vertical-align:top"><p>1 (0.6%)</p></td><td style="vertical-align:top"><p>2 (1.1%)</p></td><td style="vertical-align:top; width:184px"><p>3 (1.7%)</p></td></tr><tr><td style="vertical-align:top"><p>PR, n (%)</p></td><td style="vertical-align:top"><p>143 (79.9)</p></td><td style="vertical-align:top"><p>150 (83.8)</p></td><td style="vertical-align:top; width:184px"><p>128 (72.3)</p></td></tr><tr><td style="vertical-align:top"><p>PRL, n (%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2 (1.1)</p></td><td style="vertical-align:top; width:184px"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>SD, n (%)</p></td><td style="vertical-align:top"><p>4 (2.2)</p></td><td style="vertical-align:top"><p>8 (4.5)</p></td><td style="vertical-align:top; width:184px"><p>15 (8.5)</p></td></tr><tr><td style="vertical-align:top"><p>PD, n (%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>3 (1.7)</p></td><td style="vertical-align:top; width:184px"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Non-evaluable, n (%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1 (0.6)</p></td><td style="vertical-align:top; width:184px"><p>8 (4.5)</p></td></tr><tr><td style="vertical-align:top"><p>Unknown, n (%)</p></td><td style="vertical-align:top"><p>6 (3.4)</p></td><td style="vertical-align:top"><p>12 (6.7)</p></td><td style="vertical-align:top; width:184px"><p>12 (6.8)</p></td></tr></tbody></table><p>CI=confidence interval; HR=hazard ratio; NR=not reached; CR=complete response; CRi=complete response with incomplete blood count recovery; nPR=nodular partial response; PR=partial response; PRL=PR with lymphocytosis; SD=stable disease; PD=progressive disease<br />*Per IRC assessment<br />&dagger;Based on stratified Cox-Proportional-Hazards model</p><p>&nbsp;</p><p>PFS results for CALQUENCE with or without obinutuzumab were consistent across subgroups, including high risk features. In the high risk CLL population (17p deletion, 11q deletion, TP53 mutation, and unmutated IGHV), the PFS HRs of CALQUENCE with or without obinutuzumab versus obinutuzumab plus chlorambucil was 0.08 [95% CI (0.04, 0.15)] and 0.13 [95% CI (0.08, 0.21)], respectively.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="15" style="vertical-align:top"><p>Number of patients at risk</p></td></tr><tr><td style="vertical-align:top"><p>Month</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>39</p></td></tr><tr><td style="vertical-align:top"><p>Calquence</p></td><td style="vertical-align:top"><p>179</p></td><td style="vertical-align:top"><p>166</p></td><td style="vertical-align:top"><p>161</p></td><td style="vertical-align:top"><p>157</p></td><td style="vertical-align:top"><p>153</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>148</p></td><td style="vertical-align:top"><p>147</p></td><td style="vertical-align:top"><p>103</p></td><td style="vertical-align:top"><p>94</p></td><td style="vertical-align:top"><p>43</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Calquence+G</p></td><td style="vertical-align:top"><p>179</p></td><td style="vertical-align:top"><p>176</p></td><td style="vertical-align:top"><p>170</p></td><td style="vertical-align:top"><p>168</p></td><td style="vertical-align:top"><p>163</p></td><td style="vertical-align:top"><p>160</p></td><td style="vertical-align:top"><p>159</p></td><td style="vertical-align:top"><p>155</p></td><td style="vertical-align:top"><p>109</p></td><td style="vertical-align:top"><p>104</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>GClb</p></td><td style="vertical-align:top"><p>177</p></td><td style="vertical-align:top"><p>162</p></td><td style="vertical-align:top"><p>157</p></td><td style="vertical-align:top"><p>151</p></td><td style="vertical-align:top"><p>136</p></td><td style="vertical-align:top"><p>113</p></td><td style="vertical-align:top"><p>102</p></td><td style="vertical-align:top"><p>86</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>2</p></td></tr></tbody></table><p><u>PFS results for CALQUENCE with or without obinutuzumab were consistent across subgroups, including high risk features. In the high risk CLL population (17p deletion, 11q deletion, TP53 mutation, and unmutated IGHV), the PFS HRs of CALQUENCE with or without obinutuzumab&nbsp;versus obinutuzumab plus chlorambucil was 0.08 [95% CI (0.04, 0.15)] and 0.13 [95% CI (0.08, 0.21)], respectively.</u></p><p><u><em>Patients with CLL who received at least one prior therapy</em><br />The safety and efficacy of CALQUENCE in relapsed or refractory CLL were evaluated in a randomised, multi-centre, open-label phase 3 study (ASCEND) of 310 patients who received at least one prior therapy. Patients received CALQUENCE monotherapy or investigator&rsquo;s choice of either idelalisib plus rituximab or bendamustine plus rituximab. The trial allowed patients to receive antithrombotic agents other than warfarin or equivalent vitamin K antagonists.</u></p><p><u>Patients were randomised 1:1 to receive either:<br />&bull; CALQUENCE 100 mg twice daily until disease progression or unacceptable toxicity, or<br />&bull; Investigator&rsquo;s choice:</u></p><p style="margin-left:40px"><u>o Idelalisib 150 mg twice daily until disease progression or unacceptable toxicity in combination with &le; 8 infusions of rituximab (375 mg/m2/500 mg/m2) on Day 1 of each 28-day cycle for up to 6 cycles<br />o Bendamustine 70 mg/m2 (Day 1 and 2 of each 28-day cycle) in combination with rituximab (375 mg/m2/500 mg/m2) on Day 1 of each 28-day cycle for up to 6 cycles.</u></p><p><u>Patients were stratified by 17p deletion mutation status (presence versus absence), ECOG performance status (0 or 1 versus 2) and number of prior therapies (1 to 3 versus &ge; 4). After confirmed disease progression, 35 patients randomised on investigator&rsquo;s choice of either idelalisib plus rituximab or bendamustine plus rituximab crossed over to CALQUENCE. Table 8 summarizes the baseline demographics and disease characteristics of the study population.</u></p><p><strong>Table 8. Baseline patient characteristics in (ASCEND) patients with CLL</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:552px"><thead><tr><td style="vertical-align:top"><p><strong>Characteristic</strong></p></td><td style="vertical-align:top"><p><strong>Calquence monotherapy</strong></p><p><strong>N=155</strong></p><p>&nbsp;</p></td><td style="vertical-align:top; width:142px"><p><strong>Investigator&rsquo;s choice of idelalisib + rituximab or bendamustine + rituximab</strong></p><p><strong>N=155</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Age, years; median (range)</p></td><td style="vertical-align:top"><p>68 (32-89)</p></td><td style="vertical-align:top; width:142px"><p>67 (34-90)</p></td></tr><tr><td style="vertical-align:top"><p>Male; %</p></td><td style="vertical-align:top"><p>69.7</p></td><td style="vertical-align:top; width:142px"><p>64.5</p></td></tr><tr><td style="vertical-align:top"><p>Caucasian; %</p></td><td style="vertical-align:top"><p>93.5</p></td><td style="vertical-align:top; width:142px"><p>91.0</p></td></tr><tr><td style="vertical-align:top"><p>ECOG performance status; %</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>&nbsp;37.4</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;35.5</p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>50.3</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;51.0</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>&nbsp;12.3</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;13.5</p></td></tr><tr><td style="vertical-align:top"><p>Median time from diagnosis (months)</p></td><td style="vertical-align:top"><p>85.3</p></td><td style="vertical-align:top; width:142px"><p>79.0</p></td></tr><tr><td style="vertical-align:top"><p>Bulky disease with nodes &ge; 5 cm; %</p></td><td style="vertical-align:top"><p>49.0</p></td><td style="vertical-align:top; width:142px"><p>48.4</p></td></tr><tr><td style="vertical-align:top"><p>Median number of prior CLL therapies (range)</p></td><td style="vertical-align:top"><p>1 (1-8)</p></td><td style="vertical-align:top; width:142px"><p>2 (1-10)</p></td></tr><tr><td style="vertical-align:top"><p>Number of Prior CLL Therapies; %</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>&nbsp;52.9</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;43.2</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>&nbsp;25.8</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;29.7</p></td></tr><tr><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>&nbsp;11.0</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;15.5</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 4</p></td><td style="vertical-align:top"><p>&nbsp;10.3</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;11.6</p></td></tr><tr><td style="vertical-align:top"><p>Cytogenetics/FISH Category; %</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>17p deletion</p></td><td style="vertical-align:top"><p>18.1</p></td><td style="vertical-align:top; width:142px"><p>13.5</p></td></tr><tr><td style="vertical-align:top"><p>11q deletion</p></td><td style="vertical-align:top"><p>25.2</p></td><td style="vertical-align:top; width:142px"><p>28.4</p></td></tr><tr><td style="vertical-align:top"><p>TP53 mutation</p></td><td style="vertical-align:top"><p>25.2</p></td><td style="vertical-align:top; width:142px"><p>21.9</p></td></tr><tr><td style="vertical-align:top"><p>Unmutated IGHV</p></td><td style="vertical-align:top"><p>76.1</p></td><td style="vertical-align:top; width:142px"><p>80.6</p></td></tr><tr><td style="vertical-align:top"><p>Complex karyotype (&ge;3 abnormalities)</p></td><td style="vertical-align:top"><p>32.3</p></td><td style="vertical-align:top; width:142px"><p>29.7</p></td></tr><tr><td style="vertical-align:top"><p>Rai Stage; %</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; 0</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top; width:142px"><p>2.6</p></td></tr><tr><td style="vertical-align:top"><p>I</p></td><td style="vertical-align:top"><p>&nbsp;25.2</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;20.6</p></td></tr><tr><td style="vertical-align:top"><p>II</p></td><td style="vertical-align:top"><p>&nbsp;31.6</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;34.8</p></td></tr><tr><td style="vertical-align:top"><p>III</p></td><td style="vertical-align:top"><p>&nbsp;13.5</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;11.6</p></td></tr><tr><td style="vertical-align:top"><p>IV</p></td><td style="vertical-align:top"><p>&nbsp;28.4</p></td><td style="vertical-align:top; width:142px"><p>&nbsp;29.7</p></td></tr></tbody></table><p><u>The primary endpoint was PFS as assessed by IRC IWCLL 2008 criteria with incorporation of the clarification for treatment-related lymphocytosis (Cheson 2012). With a median follow-up of 16.1 months, PFS indicated a 69% statistically significant reduction in the risk of death or progression for patients in the CALQUENCE Arm. At the time of analysis, median overall survival had not been reached in any arm with a total of 33 deaths: 15 (9.7%) in the CALQUENCE monotherapy arm and 18 (11.6%) in the investigator&rsquo;s choice of either idelalisib plus rituximab or bendamustine plus rituximab arm. Efficacy results are presented in Table 9. The Kaplan-Meier curve for PFS is shown in Figure 2.</u></p><p><strong>Table 9. Efficacy results per IRC Assessments in (ASCEND) patients with CLL</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:649px"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Calquence monotherapy</strong></p><p><strong>N=155</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Investigator&rsquo;s choice of idelalisib + rituximab or bendamustine + rituximab</strong></p><p><strong>N=155</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Progression-free survival<sup>*</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of events (%)</p></td><td style="vertical-align:top"><p>27 (17.4)</p></td><td style="vertical-align:top"><p>68 (43.9)</p></td></tr><tr><td style="vertical-align:top"><p>PD, n (%)</p></td><td style="vertical-align:top"><p>19 (12.3)</p></td><td style="vertical-align:top"><p>59 (38.1)</p></td></tr><tr><td style="vertical-align:top"><p>Death events (%)</p></td><td style="vertical-align:top"><p>8 (5.2)</p></td><td style="vertical-align:top"><p>9 (5.8)</p></td></tr><tr><td style="vertical-align:top"><p>Median (95% CI), months</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>16.5 (14.0, 17.1)</p></td></tr><tr><td style="vertical-align:top"><p>HR<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.31 (0.20, 0.49)</p></td></tr><tr><td style="vertical-align:top"><p>P-value</p></td><td colspan="2" style="vertical-align:top"><p>&lt; 0.0001</p></td></tr><tr><td style="vertical-align:top"><p>15 months estimate, % (95% CI)</p></td><td style="vertical-align:top"><p>82.6 (75.0, 88.1)</p></td><td style="vertical-align:top"><p>54.9 (45.4, 63.5)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Overall survival<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Death events (%)</p></td><td style="vertical-align:top"><p>15 (9.7)</p></td><td style="vertical-align:top"><p>18(11.6)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard Ratio (95% CI)<sup> &dagger;</sup></p></td><td style="vertical-align:top"><p>0.84 (0.42, 1.66)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Best overall response rate<sup>*</sup> (CR + CRi + nPR + PR)**</strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR, n (%)</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>126 (81.3)</p><p>(74.4, 86.6)</p></td><td style="vertical-align:top"><p>117 (75.5)</p><p>(68.1, 81.6)</p></td></tr><tr><td style="vertical-align:top"><p>P-value</p></td><td style="vertical-align:top"><p>0.2248</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>CR, n (%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2 (1.3)</p></td></tr><tr><td style="vertical-align:top"><p>PR, n (%)</p></td><td style="vertical-align:top"><p>126 (81.3)</p></td><td style="vertical-align:top"><p>115 (74.2)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Duration of Response (DoR)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median (95% CI), months</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>13.6 (11.9,NR)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>CI=confidence interval; HR=hazard ratio; NR=not reached; CR=complete response; CRi=complete response with incomplete blood count recovery; nPR=nodular partial response; PR=partial response; PD=progressive disease</p><p><sup>*</sup>Per IRC assessment</p><p><sup>a</sup> Median OS not reached for both arms. P&lt;0.6089 for OS.</p><p>**CRi and nPR have values of 0.</p><p><sup>&dagger;</sup>Based on stratified Cox-Proportional-Hazards model</p></td></tr></tbody></table><p>With long term data, the median follow-up was 22.1 months for Calquence and 21.9 months for the IR/BR. The median PFS was not reached in Calquence and was 16.8 months in IR/BR. The hazard ratio of INV-assessed PFS of Calquence compared with IR/BR was 0.27 [95% CI, 0.18 to 0.40] representing a 73% reduction in the risk of death or progression for patients in the Calquence arm. Efficacy results per Investigator Assessments (INV) are presented in Table 10.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Acalabrutinib exhibits dose-proportionality, and both acalabrutinib and its active metabolite, ACP-5862, exposures increase with dose across a dose range of 75 to 250 mg (0.75 to 2.5 times the approved recommended single dose) in patients with B-cell malignancies. At the recommended dose of 100 mg twice daily, the geometric mean (% coefficient of variation [CV]) daily area under the plasma drug concentration over time curve (AUC24h) and maximum plasma concentration (Cmax) for acalabrutinib were 1843 (38%) ng&bull;h/mL and 563 (29%) ng/mL, respectively, and for ACP-5862 were 3947 (43%) ng&bull;h/mL and 451 (52%) ng/mL, respectively.</u></p><p>&nbsp;</p><p><strong>Absorption</strong><br /><u>The geometric mean absolute bioavailability of acalabrutinib was 25%. Median [min, max] time to peak acalabrutinib plasma concentrations (Tmax) was 0.9 [0.5, 1.9] hours, and 1.6 [0.9, 2.7] hour for ACP-5862.</u></p><p><strong>Distribution</strong><br /><u>Reversible binding to human plasma protein was 97.5% for acalabrutinib and 98.6% for ACP-5862. The in vitro mean blood-to-plasma ratio was 0.8 for acalabrutinib and 0.7 for ACP-5862. The geometric mean (% CV) steady state volume of distribution (Vss) was approximately 101 (52%) L for acalabrutinib and 67 (32%) L for ACP-5862.</u></p><p><strong>Biotransformation/Metabolism</strong><br />Acalabrutinib is predominantly metabolized by CYP3A enzymes, and to a minor extent, by glutathione conjugation and amide hydrolysis, based on in vitro studies. ACP-5862 was identified as the major active metabolite in plasma with a geometric mean exposure (AUC) that was approximately 2- to 3-fold higher than the exposure of acalabrutinib. ACP-5862 is approximately 50% less potent than acalabrutinib with regard to BTK inhibition.</p><p><strong>Elimination</strong><br /><u>The geometric mean (% CV) terminal elimination half-life (t1/2) was 1 (59%) hour for acalabrutinib and 3.5 (24%) hours for ACP-5862. The geometric mean (%CV) apparent oral clearance (CL/F) was 71 (35%) L/hr for acalabrutinib and 13 (42%) L/hr for ACP-5862.</u> Following administration of a single 100 mg radiolabeled acalabrutinib dose in healthy subjects, 84% of the dose was recovered in the feces and 12% of the dose was recovered in the urine, with less than 2% of the dose excreted as unchanged acalabrutinib in<u> urine and feces.</u></p><p><strong>Pharmacokinetics in Special Populations</strong><br /><em>Age, Race, and Body Weight</em><br /><u>Age (32 to 90 years), sex, race (Caucasian, African American), and body weight (40 to 149 kg) did not have clinically meaningful effects on the PK of acalabrutinib and its active metabolite, ACP-5862.</u></p><p><em>Renal Impairment</em><br /><u>No clinically relevant PK difference was observed in patients with mild or moderate renal impairment (eGFR &ge; 30 mL/min/1.73m2, as estimated by MDRD (modification of diet in renal disease equation)). Acalabrutinib PK has not been evaluated in patients with severe renal impairment (eGFR &lt; 29 mL/min/1.73m2, MDRD) or renal impairment requiring dialysis.</u></p><p><em>Hepatic Impairment</em><br />The AUC of acalabrutinib increased 1.9-fold in subjects with mild hepatic impairment (Child-Pugh class A), 1.5-fold in subjects with moderate hepatic impairment (Child-Pugh class B) and 5.3-fold in subjects with severe hepatic impairment (Child-Pugh class C) compared to subjects with normal liver function. No clinically relevant PK difference in ACP-5862 was observed in subjects with severe hepatic impairment (Child-Pugh Class C) compared to subjects with normal liver function. No clinically relevant PK differences in acalabrutinib and ACP-5862 were observed in patients with mild or moderate hepatic impairment (total bilirubin less and equal to upper limit of normal [ULN] and AST greater than ULN, or total bilirubin greater than ULN and any AST) relative to patients with normal hepatic function (total bilirubin and AST within ULN).</p><p><u>Drug Interaction Studies</u><br /><em>Effect of CYP3A Inhibitors on Acalabrutinib</em><br />Co-administration with a strong CYP3A inhibitor (200 mg itraconazole once daily for 5 days) increased acalabrutinib Cmax by 3.7-fold and AUC by 5.1-fold in healthy subjects (N=17).</p><p><em>Effect of CYP3A Inducers on Acalabrutinib</em><br />When accounting for both acalabrutinib and its active metabolite, ACP-5862, PBPK simulations with strong CYP3A inducers showed a 21-51% decrease in total AUC of active components. Simulations with a moderate CYP3A inducer (efavirenz) showed a 25% decrease in total AUC of active components.</p><p><em>Gastric Acid Reducing Agents</em><br />Acalabrutinib solubility decreases with increasing pH. Co-administration with an antacid (1 g calcium carbonate) decreased acalabrutinib AUC by 53% in healthy subjects. Co-administration with a proton pump inhibitor (40 mg omeprazole for 5 days) decreased acalabrutinib AUC by 43%<em> [see interaction with other medicinal products and other forms of interaction (4.5)].</em></p><p><em><u>In Vitro Studies</u></em></p><p><em>Metabolic Pathways</em><br />Acalabrutinib is a weak inhibitor of CYP3A4/5, CYP2C8 and CYP2C9, but does not inhibit CYP1A2, CYP2B6, CYP2C19, CYP2D6. UGT1A1, and UGT2B7 ACP-5862 is a weak inhibitor of CYP2C8, CYP2C9 and CYP2C19, but does not inhibit CYP1A2, CYP2B6, CYP2D6 ,CYP3A4/5 , UGT1A1, and UGT2B7.</p><p>Acalabrutinib is a weak inducer of CYP1A2, CYP2B6 and CYP3A4; ACP-5862 weakly induces CYP3A4.</p><p><em>Drug Transporter Systems</em><br />Acalabrutinib and its active metabolite, ACP-5862, are substrates of P-glycoprotein (P-gp) breast cancer resistance protein and BCRP. Acalabrutinib is not a substrate of renal uptake transporters OAT1, OAT3, and OCT2, or hepatic transporters OATP1B1, and OATP1B3. ACP-5862 is not a substrate of OATP1B1 or OATP1B3. ACP-5862 is not a substrate of OATP1B1 or OATP1B3.</p><p>Acalabrutinib and ACP-5862 do not inhibit P-gp, OAT1, OAT3, OCT2, OATP1B1, OATP1B3 , and MATE2-K at clinically relevant concentrations.</p><p><br />Acalabrutinib may inhibit intestinal BCRP substrates (see section 4.5), while ACP-5862 may inhibit MATE1 (see Section 4.5) at clinically relevant concentrations. Acalabrutinib does not inhibit MATE1, while ACP-5862 does not inhibit BCRP at clinically relevant concentrations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Carcinogenicity</strong><br />Carcinogenicity studies have not been conducted with acalabrutinib.</p><p><strong>Genotoxicity/Mutagenicity</strong><br />Acalabrutinib was not mutagenic in an in vitro bacterial reverse mutation (AMES) assay or clastogenic in an in vitro human lymphocyte chromosomal aberration assay or in an in vivo rat bone marrow micronucleus assay.</p><p><strong>Repeat-dose toxicity</strong><br />Daily oral administration of acalabrutinib for up to 6 months duration in rats and 9 months in dogs was tolerated at exposure levels that exceed human therapeutic exposures at the recommended dose ( 2.5-fold in rats, 8.2-fold in dogs, based on AUC).</p><p>In rats, renal effects including tubular degeneration were observed at exposures 7 times or greater than that of the recommended human dose. Renal effects were reversible with complete recovery in rats exposed at levels 4.2 times the recommended human dose and partial recovery in rats at the higher exposures ( 6.8-fold or greater).</p><p>In rats, dose-responsive reversible liver findings including individual hepatocyte necrosis were observed after exposures 4.2 times or greater than that of the recommended human dose.</p><p>Cardiac toxicities (myocardial haemorrhage, inflammation, necrosis) were observed in rats that died during the study and at exposures equivalent to 6.8 times or greater than that of the human recommended dose. Reversibility for the heart findings could not be assessed as these findings were only observed at doses above the maximum tolerated dose (MTD). At exposures representing 4.2 times the human recommended dose, no cardiac toxicities were observed.</p><p><strong>Reproductive toxicology</strong><br />No effects on fertility were observed in male or female rats at exposures 10 or 9 times the human AUC exposure at the recommended dose, respectively.</p><p>In a combined fertility and embryofoetal development study in female rats, acalabrutinib was administered orally at doses up to 200 mg/kg/day starting 14 days prior to mating through gestational day [GD] 17. No effects on embryofoetal development and survival were observed . The AUC at 200 mg/kg/day in pregnant rats was approximately 9 times the AUC in patients at the recommended dose of 100 mg twice daily. The presence of acalabrutinib and its active metabolite were confirmed in foetal rat plasma.</p><p>In an embryofoetal study in pregnant rabbits, acalabrutinib was administered orally at doses up to 200 mg/kg/day during the period of organogenesis (from GD 6-18). Acalabrutinib produced no maternal toxicity and no evidence of teratogenicity or foetal development, growth, or survival at doses of 50 mg/kg/day (approximately equivalent to the human AUC exposure at the recommended dose). Decreased foetal body weight and delayed ossification were observed at exposure levels that produced maternal toxicity (doses &ge; 100 mg/kg/day), which were 2.4-times greater than the human exposure levels at the recommended dose.</p><p>In a rat reproductive study, dystocia (prolonged /difficult labour) was observed at exposures &gt; 2.3-times the clinical exposure at 100 mg twice daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule Content</u>: microcrystalline cellulose, colloidal silicon dioxide, partially pregelatinized starch (maize), magnesium stearate (E572), and sodium starch glycolate (Type A).</p><p><br /><u>Capsule Shell:</u> gelatine, titanium dioxide (E171), yellow iron oxide (E172), and FD&amp;C Blue 2 (Indigotine/Indigo carmine) (E132).</p><p><br /><u>Printing Ink</u>: Shellac, black iron oxide (E172), propylene glycol (E1520), ammonium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do Not Store Above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium /Aluminium blisters. Cartons of 6 x 10 capsules.<br />Pack sizes may vary by market.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AstraZeneca AB 
SE-151 85
Sodertalje
Sweden
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2022 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>